Skip to main content

Table 2 Demography of patients in included studies

From: Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis

Author

Year

Age (year)

Male (%)

Number

Aetiology of liver disease

Alcoholic

HBV

HCV

NAFLD

Others

Control

Statin

Control

Statin

Control

Statin

Control

Statin

Control

Statin

Control

Statin

Control

Statin

Control

Statin

Abraldes, et al

2009

56 ± 10

58 ± 10

21

17

27

28

12

11

2

0

13

4

–

–

0

3

Kumar, et al

2014

59.6 ± 10.6

59.8 ± 10.9

88 (54.32)

44 (54.3)

162

81

39 (24.1)

18 (22.2)

10 (6.2)

2 (2.5)

55 (34)

18 (22.2)

41 (25.3)

35 (43.2)

6 (3.7)

3 (3.7)

Pollo-Flores, et al

2015

58.5 ± 13.5

56.5 ± 8.7

50%

57%

20

14

4

3

5

4

7

9

none

none

1

1

Simon, et al

2015

50.1 ± 7.2

54.2 ± 7.2

71.2

58.6

514

29

none

none

none

none

all

all

none

none

none

none

Yang, et al

2015

NG

NG

23,602 (42)

11,801 (42)

56,142

28,071

none

none

none

none

all

all

none

none

none

none

Mohanty, et al

2016

54 (50–58)

56 (52–60)

671 (97.9)

677 (98.8)

685

685

none

none

none

none

all

all

none

none

none

None

Huang, et al

2016

49.7 ± 11.5

50 ± 11.1

3479 (53.2)

3454 (52.8)

6543

6543

none

none

all

all

none

none

none

none

none

None

Simon, et al

2016

52.5 ± 6.9

53.5 ± 5.9

95.37

96.16

4970

4165

none

none

none

none

all

all

none

none

none

none

Abraldes, et al

2016

57.6 ± 10.6

57.4 ± 11.3

53 (67.9)

45 (65.2)

78

69

55 (71.4)

49 (71)

2 (2.6)

1 (1.4)

17 (22.1)

19 (27.5)

4 (5.2)

1 (1.4)

11

6

Wani, et al

2017

58.5 ± 6

58.5 ± 6

21

21

38

38

12

12

15

15

15

15

11

11

none

none

Wong, et al

2017

59.9 ± 13.9

60 ± 13.1

21,835 (58.8)

1266 (61.7)

67,131

2053

none

none

61,692 (89.7)

1867 (90.9)

4925 (8.9)

158 (7.7)

none

none

514 (0.8)

28 (1.4)

Bang, et al

2017

54 ± 10

57 ± 9

60%

61%

496

248

all

all

none

none

none

none

none

none

none

None

Chang, et al

2017

57.5 ± 14.1

56.5 ± 11.2

476 (71)

492 (73)

675

675

231 (34)

216 (32)

292 (43)

313 (46)

152 (23)

146 (22)

none

none

none

none

Kim, et al

2017

61.8 ± 9.2

61.8 ± 9.2

6860 (83.6)

1372 (83.6)

8210

1642

not given

Bishnu, et al

2018

46.7 (7.1)

44 ± 12.7

12 (100)

9 (81.2)

12

11

6 (50)

4 (36.4)

1 (8.3)

0

0

0

1 (8.33)

0

1 (8.33)

1 (9.09)

Kaplan, et al

2019

63 (58–68)

63 (58–67)

98%

98

12,860

6481

4876 (35.2)

2334 (36)

none

none

2065 (14.9)

933 (14.4)

2159 (15.6)

1042 (16.1)

none

none

Elwan, et al.

2019

50.8 ± 7

51.5 ± 6.7

16 (80)

10 (50)

20

20

none

none

HCV 38, HBV 1, HCV + HBV 1

none

none

none

  1. SD Standard deviation, IQR Interquartile range, HBV Hepatitis B virus, HCV Hepatitis C virus, NAFLD Non-alcoholic fatty liver disease